Dietary Cysteine and Methionine Deprivation (CMD) in Glioma Patients
Key facts
- Who runs it
- UNC Lineberger Comprehensive Cancer Center
- Where
- Chapel Hill, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- May 2026
- Expected to end
- Jul 2028
- Type of study
- Interventional, 6 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Normal diet
- Cysteine/methionine deprivation (CMD) diet for 2 days
- Cysteine/methionine deprivation (CMD) diet for 4 days
- Record updated
- 28 April 2026
- Why it stopped
- Not stated
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information
- Subjects is willing and able to comply with study procedures based on the judgement of the investigator
- Age ≥ 18 years at the time of consent
- Karnofsky Performance Status of ≥ 60 assessed at diagnosis
Who cannot take part
- Subjects with prior brain metastasis
- Active infection requiring systemic therapy
- Any active disease that may be associated with unacceptable anesthetic/operative risk
- Pregnant or breastfeeding
- Transfusion within 7 days of diet initiation
Other criteria
- In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Eligibility must be maintained up until the point at which the subject receives treatment for the subject to be considered eligible for treatment
Where in United States
- University of North Carolina at Chapel Hill, Department of Radiation OncologyChapel Hill, United States
About the trial
What the trial wants to find out
This pilot study looks at how certain diet changes affect the body in patients with recurrent brain tumors (glioma) who are planning to have standard treatment like radiation or surgery. Up to 30 patients will be randomly assigned to either a regular diet or a special diet that limits two nutrients (cysteine and methionine) for 2, 4, or 7 days before their treatment.
Read full original descriptionShow less
Patients will be monitored for side effects using blood tests and questionnaires, and patients will keep a diary to track how well they follow the diet. Blood and urine samples will be used to see how the diet affects the body. Tumor samples (from surgery) will help researchers study how the cancer cells behave, and stool samples will be used to look at gut bacteria.
This is a randomized, blinded interventional pilot study to measure glutathione metabolite levels with a cysteine/methionine deprivation (CMD) diet in glioma patients. A menu of pre-prepared meals will be provided to subjects that consist of either a control diet or a CMD diet. The CMD diet will be implemented simultaneously in 2 cohorts of participants with recurrent glioma.
The primary objective will be to measure the metabolic state of glioblastome multiforme tumor cells through dietary restriction of the sulfur-containing amino acids (SAA), cysteine/cystine and methionine.
Patient from cohort A can later be included in Cohort B if applicable. Patients will be followed for progression free survival and overall survival for up to 1 year, or until they discontinue or are removed from the study for exploratory endpoints.
The 6 groups in the trial
- Cohort A: Surgery ControlExisting treatment, for comparison
Participants will undergo surgery and receive a normal diet.
Treatment: Normal diet
- Cohort A: Surgery Diet Restriction 2 daysTreatment being tested
Participants will undergo surgery and receive a cysteine/methionine deprivation (CMD) diet for 2 days.
Treatment: Cysteine/methionine deprivation (CMD) diet for 2 days
- Cohort A: Surgery Diet Restriction 4 daysTreatment being tested
Participants will undergo surgery and receive a cysteine/methionine deprivation (CMD) diet for 4 days.
Treatment: Cysteine/methionine deprivation (CMD) diet for 4 days
- Cohort B: Radiation Therapy ControlExisting treatment, for comparison
Participants will undergo radiation therapy and receive a normal diet.
Treatment: Normal diet
- Cohort B: Radiation Therapy 2 daysTreatment being tested
Participants will undergo radiation therapy and receive a a cysteine/methionine deprivation (CMD) diet for 2 days.
Treatment: Cysteine/methionine deprivation (CMD) diet for 2 days
- Cohort B: Radiation Therapy 4 daysTreatment being tested
Participants will undergo radiation therapy and receive a a cysteine/methionine deprivation (CMD) diet for 4 days.
Treatment: Cysteine/methionine deprivation (CMD) diet for 4 days
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study Examining Dietary Restriction of Sulfur Containing Amino Acids by Cysteine and Methionine Deprivation (CMD) in Glioma Patients
- Record updated
- 28 April 2026